Get the Stockscreener App
10.15
4.15%
-0.44
Omeros Corporation stock is traded at $10.15, with a volume of 1.11M.
It is down -4.15% in the last 24 hours and up +47.31% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$10.59
Open:
$10.605
24h Volume:
1.11M
Relative Volume:
0.32
Market Cap:
$719.64M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-5.3989
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-6.45%
1M Performance:
+47.31%
6M Performance:
+185.92%
1Y Performance:
+19.55%
1-Day Range:
$10.15
$10.71
1-Week Range:
$10.15
$11.71
52-Week Range:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
10.15 | 750.84M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
Omeros (NASDAQ:OMER) Trading Down 5.1%Here's What Happened - MarketBeat
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz - Insider Monkey
Omeros Corporation's (NASDAQ:OMER) Shift From Loss To Profit - Yahoo Finance
Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval? - Insider Monkey
Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Omeros Completes Major Asset Deal with Novo Nordisk - MSN
Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? - MSN
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
Omeros (NASDAQ:OMER) Stock Price Up 8.2%Still a Buy? - MarketBeat
Can Omeros Corporation stock outperform in 2025 bull marketJuly 2025 Update & Short-Term High Return Ideas - Newser
11 Best Micro-Cap Stocks to Invest in According to Analysts - Insider Monkey
Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital - MarketBeat
Aug Sentiment: Is Omeros Corporation stock attractive for income investorsMarket Volume Report & Smart Allocation Stock Tips - moha.gov.vn
How Omeros Corporation stock performs in weak economyChart Signals & Entry Point Confirmation Alerts - Newser
Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Cap - GuruFocus
Omeros Shares Jump After Finalizing $340 Million Novo Nordisk Deal - MSN
Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - MSN
Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus
Omeros Closes Asset Purchase, Licensing Deal With Novo Nordisk for Zaltenibart - MarketScreener
Omeros, Novo Nordisk Close Up to $2.1B Deal for Rare Disease Drug Zaltenibart, NOVO Stock - Somos Hermanos -
Omeros receives $240 million upfront from Novo Nordisk deal By Investing.com - Investing.com Canada
Omeros receives $240 million upfront from Novo Nordisk deal - Investing.com
Omeros stock surges after closing $340 million deal with Novo Nordisk - Investing.com Australia
Omeros stock surges after closing $340 million deal with Novo Nordisk By Investing.com - Investing.com South Africa
Omeros closes asset purchase and license deal with Novo Nordisk for MASP-3 inhibitor zaltenibart - marketscreener.com
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Yahoo Finance
Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - simplywall.st
What catalysts could drive Omeros Corporation stock higher2025 Short Interest & Weekly Top Stock Performers List - moha.gov.vn
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha
What technical signals suggest for Omeros Corporation stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Omeros Corporation Stock Analysis and ForecastInsider Selling Patterns & Free Stock Trading Workshops - earlytimes.in
Is Omeros Corporation stock cheap compared to fundamentalsIPO Watch & Technical Entry and Exit Tips - newser.com
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Omeros (NASDAQ:OMER) Shares Down 5.6%Should You Sell? - MarketBeat
Here's Why Shares in Theravance Biopharma Exploded Today - AOL.com
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com
How strong is Omeros Corporation stock revenue growthBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Omeros (NASDAQ:OMER) Stock Price Up 8.1%Time to Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Q3 2025 Earnings Call Transcript - Insider Monkey
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying - AOL.com
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):